Quantcast

Latest Zidovudine Stories

2014-10-16 08:30:41

RICHMOND, Calif., Oct. 16, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that Company scientists and clinicians, as well as academic collaborators, were invited speakers at three major scientific meetings in Europe and the United States. Their presentations covered a number of therapeutic uses of Sangamo's novel zinc finger protein (ZFP) technology, but were primarily focused on reviewing the progress of the Company's ZFP Therapeutic(®) program in HIV/AIDS....

2014-10-14 16:25:39

LONDON, Oct. 14, 2014 /PRNewswire/ -- STUDY GOALS AND OBJECTIVESThe aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for products used in the treatment, testing and prophylaxis of HIV/AIDS. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2018; these are based on industry sources and considered assessment of the regulatory...

2014-10-06 08:28:05

- Product strengthens growing antiretroviral franchise in the U.S. - PITTSBURGH, Oct. 3, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg, which is the generic version of Viiv's Combivir(®). Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of HIV-1 infection in...

2014-09-25 08:26:56

GENEVA, September 25, 2014 /PRNewswire/ -- MPP signs sub-licences with six generic manufacturers for the development of Phase III drug Tenofovir Alafenamide Two months after signing a licence with Gilead Sciences, Inc. for the company's novel investigational medicine tenofovir alafenamide (TAF), MPP announced six new sub-licences with Aurobindo, Cipla, Desano, Emcure, Hetero Labs and Laurus Labs to allow generic manufacture of TAF for...

2014-09-16 12:31:01

Study finds HIV medication specialist improved care, lowered costs ROCKVILLE, Md., Sept. 16, 2014 /PRNewswire-USNewswire/ -- A recent study conducted by a team of researchers from Kaiser Permanente's Mid-Atlantic Region found that the introduction of an HIV clinical pharmacist improved medication adherence, resulting in better health outcomes and lower costs for HIV positive patients. The study states that non-adherence to antiretroviral therapy (ART) has been associated with...

2014-08-19 08:29:32

VANCOUVER, Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs. The study, conducted by ImmuneCarta®, the immune monitoring business unit of Caprion, evaluated in vitro effectiveness of Oral Amp B in reactivating latent HIV viral reservoirs which remain present in individuals despite intensive treatment with...

2014-08-05 11:54:33

BMJ-British Medical Journal Antiretroviral drugs and chronic immune system suppression might explain link HIV infection is linked to a significantly lower risk of developing multiple sclerosis (MS), indicates observational research published online in the Journal of Neurology Neurosurgery & Psychiatry. Chronic dampening down of the immune system as a result of the infection and/or the antiretroviral drugs used to treat it might explain this association, say the researchers....

2014-07-25 09:45:29

University of Cincinnati Academic Health Center Treatment of HIV patients co-infected with the hepatitis C virus (HCV) with an anti-retroviral drug therapy not only tackles HIV, but also reduces HCV replication, according to a new study lead by a University of Cincinnati researcher. The results were published Wednesday, July 23, 2014, in Science Translational Medicine. Previously, physicians treating co-infected patients worried that HIV antiretroviral therapy might injure the liver...

2014-07-24 10:43:07

Temple University Health System Their approach promises a permanent cure and potential for protection against HIV The HIV-1 virus has proved to be tenacious, inserting its genome permanently into its victims' DNA, forcing patients to take a lifelong drug regimen to control the virus and prevent a fresh attack. Now, a team of Temple University School of Medicine researchers has designed a way to snip out the integrated HIV-1 genes for good. "This is one important step on the path...

2014-07-24 00:21:34

MELBOURNE, Australia, July 24, 2014 /PRNewswire/ -- Announced at the 20th International AIDS Conference in Melbourne, the agreement seeks to increase access to a promising new HIV medicine in 112 developing countries At the AIDS 2014 conference in Melbourne today, the Medicines Patent Pool (MPP) announced a new licensing agreement with Gilead Sciences for tenofovir alafenamide (TAF), a promising new medicine currently...


Latest Zidovudine Reference Libraries

0_a4499f7c8759b5cbe79bad5eca319070
2011-01-26 14:08:59

Human immunodeficiency virus (HIV), a lentivirus, causes acquired immunodeficiency syndrome (AIDS) which is a condition in humans were the immune system begins to fail, leading to life-threatening opportunistic infections. Infection is transferred through bodily fluids where HIV is present as both free virus particles and within infected immune cells. The four most common routes of infection are unsafe sex, contaminated needles, breast milk, and transmission from an infected mother to her...

More Articles (1 articles) »
Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related